Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions
A composition for use in treating corneal and conjunctival lesions, includes a prostaglandin F2alpha or analogue, in a therapeutic amount, the composition being in a form suitable for topical application on the ocular surface and is free of deleterious preservative. A method for treating surface ocular conditions in a patient in need thereof, includes administering an effective amount of the composition.
1. A method for treating corneal and/or conjunctival lesions in a patient in need thereof, comprising topically administering a composition comprising a therapeutic amount of a prostaglandin F2alpha or analogue thereof, as sole active agent, wherein said analogue is selected from the group consisting of latanoprost, acid-free latanoprost, 15-ketolatanoprost, latanoprost nitroxide unoprostone, bimatoprost, travoprost and tafluprost.
2. The method according to claim 1 , wherein the therapeutic amount of prostaglandin F2alpha or analogue thereof in the composition ranges from 0.0001 to 0.005% in weight to the weight of the total composition.
3. The method according to claim 1 , wherein the composition is free of deleterious preservative.
4. The method according to claim 1 , wherein the composition is an aqueous solution, a viscous or semi-viscous gel, a suspension, a solid insert or an anionic or cationic emulsion.
5. The method according to claim 1 , wherein the composition is in the form of eye drops, artificial tears, gel or ointment.
6. The method according to claim 1 , wherein the composition is isoosmotic or hypoosmotic.
7. The method according to claim 1 , wherein the composition further comprises osmoprotectants, or other healing agents, buffers, thickening agents, moisturizing agents and antioxidants agents.
8. The method according to claim 1 , wherein the composition is administered at least once per day, with a maximum of four instillations per day.
9. The method according to claim 1 , wherein the composition is administered during three to five days.
10. The method according to claim 1 , wherein the composition is unpreserved, preservative-free, self-preserved or preserved with soft preservatives.
11. The method according to claim 1 , wherein the composition further comprises an anti-glaucoma agent, an anti-inflammatory agent, an antibiotic, an antiviral or an antifungal, and other secretagogue compounds.
12. The method according to claim 1 , wherein the patient is affected by glaucoma and the therapeutic amount of prostaglandin F2alpha or analogue thereof in the composition is 0.004 to 0.005% in weight to the weight of the total composition.
13. The method according to claim 1 , wherein the patient is not affected by glaucoma, and the therapeutic amount of prostaglandin F2alpha or analogue thereof in the composition is 0.0001% to 0.004% in weight to the weight of the total composition.
14. The method according to claim 2 , wherein the composition is free of deleterious preservative.